Reading DSGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DSGN free→
Design Therapeutics, Inc. (DSGN)
NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Watch· this week
$10.72-3.77%
Close 2026-06-16 · 1-day change
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it is currently facing elevated risk with a sector backdrop that is a headwind. Compared with sector peers, it is above typical for the sector. The read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $685.15M
- Employees
- —
- IPO date
- 2021-03-05
- Next earnings
- 2026-08-06
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 0 valuation methods, at three horizons. Current price $10.72. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primary—
—consensus
Range — – —
vs price: —
Method agreement —
No-growth: today's peer multiple on trailing earnings. The headline read.
3-year—
—consensus
Range — – —
vs price: —
Method agreement —
Embeds projected growth. Leans optimistic by design. Upside context.
5-year—
—
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
no read12-month view
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Compared to peers
Not enough peers to compare yet.
Compared to its own history
Self-history needs ~20 months of data.
P/E
—
EV/EBITDA
—
FCF yield
-8.2%
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
42nd pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.77x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
stable4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
NeutralEPS revised +3.8% / 30d, n=7for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.36 → $-0.34 (+3.8% / 30d). 3 raised, 1 cut, 7 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
Material events
0 positive, 1 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: by revenue growth.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strongProvisional
- Capital allocation
- strong
- Earnings discipline
- strong
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-16
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$198.
How much price usually moves either way.
On a bad day, this stock has moved -$719.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,559.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceMonthsactive 4d
Watch for revenue growth in the sector speeding up again.
Why it matters: If revenue growth speeds up, it may signal a positive shift for Design Therapeutics.
What confirms / what disproves
Confirms:Health Care sector revenue growth is speeding up toward 10% or more.
Disproves:Revenue growth keeps slowing down below 10%.
Sector context
as of 2026-06-15
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for DSGN yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting DSGN and other Healthcare names. Worth watching these names for early signals.
- If DSGN beats again next quarter like it did this past one (a solid beat of +17% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for DSGN and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping DSGN and other Healthcare names could fade. Watch these names for early warning.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits DSGN and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-181mo agoItem 8.01
Other Events. On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”). RESTORE-FA Key Data Highlights RESTORE-FA is a Phase 1/2 clinical trial evaluating DT-216P2 in patients with FA, designed to assess safety, pharmacokinetics, pharmacodynamics, and exploratory clinical endpoints. As of May 17, 2026, 16 patients had completed treatment with weekly…
Legal / regulatorynegative
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-1.1 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.